CORRECTED-INSIGHT-Insurers scrutinize drug costs after $84,000 Sovaldi surprise
May 28, 2014 at 12:41 PM EDT
NEW YORK/LOS ANGELES, May 28 (Reuters) - Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, U.S. health insurers are trying to make sure they aren't blindsided by other drugs being developed and are looking for ways to limit their use from the day they are launched.